T. Rowe Price Associates
ELEV

T. Rowe Price Associates’s Elevation Oncology ELEV Stock Holding History

T. Rowe Price Associates’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,841
Closed -$5K – 3085
2025
Q1 		$5K Hold
16,841
– – ﹤0.01% 3033
2024
Q4 		$10K Hold
16,841
– – ﹤0.01% 3006
2024
Q3 		$11K Hold
16,841
– – ﹤0.01% 2999
2024
Q2 		$0 Buy
+16,841
New +$63.4K ﹤0.01% 2953

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

T. Rowe Price Associates's ELEV Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 16,841 shares — an estimated $5K sold.

T. Rowe Price Associates first reported a position in ELEV in Q2 2024 and held it in 4 quarters. The position peaked at $11K in Q3 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 16,841 Elevation Oncology shares in Q2 2025, an estimated $5K.
  • T. Rowe Price Associates first reported a position in Elevation Oncology in Q2 2024 and held it in 4 quarters.
  • T. Rowe Price Associates's Elevation Oncology position peaked at $11K in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.